Icosavax announced Wednesday the close of $100 million in Series B financing.

The funds will support the development of the biotech’s bivalent RSV and human metapneumovirus vaccine through initial clinical studies, continued evaluation of its virus-like particle (VLP) Covid-19 vaccine candidate, and expansion of its pipeline of other VLP vaccine candidates targeting respiratory diseases, the press release said.

Britain’s nonprofit Centre for Process Innovation (CPI) and the University of Leeds announced an agreement last week to develop a low-cost, scalable manufacturing process for a novel polio vaccine using virus-like particles.

According to Leeds’ press release, researchers will investigate over the next few months whether commercial-scale production of a shot—with reduced biosafety risks compared with today’s inactivated vaccines—is possible using CPI’s pilot manufacturing platform.